Corcept Therapeutics, Inc. is a pharmaceutical company based in the United States, focusing on the discovery and development of medications for severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of cortisol hormone. With a Risk Rating Score of 27.7, the company is considered to have a medium risk assessment. They prioritize ESG factors in their operations for sustainable growth.